Glenview Trust’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.21M | Buy |
102,463
+334
| +0.3% | +$19.5K | 0.1% | 141 |
|
|
2025
Q4 | $5.51M | Sell |
102,129
-257
| -0.3% | -$12.4K | 0.09% | 149 |
|
|
2025
Q3 | $4.62M | Sell |
102,386
-3,220
| -3% | -$150K | 0.07% | 163 |
|
|
2025
Q2 | $4.89M | Sell |
105,606
-819
| -0.8% | -$40.2K | 0.08% | 150 |
|
|
2025
Q1 | $6.49M | Sell |
106,425
-355
| -0.3% | -$20.7K | 0.13% | 125 |
|
|
2024
Q4 | $6.04M | Buy |
106,780
+4,249
| +4% | +$237K | 0.11% | 125 |
|
|
2024
Q3 | $5.3M | Buy |
102,531
+973
| +1% | +$45.6K | 0.1% | 136 |
|
|
2024
Q2 | $4.22M | Buy |
101,558
+1,419
| +1% | +$63.5K | 0.08% | 141 |
|
|
2024
Q1 | $5.43M | Buy |
100,139
+583
| +0.6% | +$29.7K | 0.12% | 129 |
|
|
2023
Q4 | $5.11M | Sell |
99,556
-10,338
| -9% | -$543K | 0.13% | 124 |
|
|
2023
Q3 | $6.38M | Buy |
109,894
+447
| +0.4% | +$27.4K | 0.18% | 108 |
|
|
2023
Q2 | $7M | Buy |
109,447
+1,082
| +1% | +$72.6K | 0.19% | 102 |
|
|
2023
Q1 | $7.51M | Sell |
108,365
-490
| -0.5% | -$34.6K | 0.22% | 101 |
|
|
2022
Q4 | $7.83M | Buy |
108,855
+2,220
| +2% | +$167K | 0.26% | 93 |
|
|
2022
Q3 | $7.58M | Sell |
106,635
-234
| -0.2% | -$17K | 0.29% | 86 |
|
|
2022
Q2 | $8.23M | Buy |
106,869
+1,110
| +1% | +$84.5K | 0.3% | 85 |
|
|
2022
Q1 | $7.72M | Sell |
105,759
-697
| -0.7% | -$46.8K | 0.25% | 89 |
|
|
2021
Q4 | $6.64M | Sell |
106,456
-4,079
| -4% | -$239K | 0.22% | 93 |
|
|
2021
Q3 | $6.54M | Sell |
110,535
-41
| -0% | -$2.7K | 0.25% | 89 |
|
|
2021
Q2 | $7.39M | Sell |
110,576
-2,784
| -2% | -$182K | 0.29% | 88 |
|
|
2021
Q1 | $7.16M | Sell |
113,360
-2,478
| -2% | -$154K | 0.31% | 86 |
|
|
2020
Q4 | $7.19M | Sell |
115,838
-1,573
| -1% | -$96.7K | 0.33% | 82 |
|
|
2020
Q3 | $7.08M | Sell |
117,411
-1,873
| -2% | -$113K | 0.37% | 74 |
|
|
2020
Q2 | $7.01M | Sell |
119,284
-1,821
| -2% | -$109K | 0.4% | 70 |
|
|
2020
Q1 | $6.75M | Sell |
121,105
-4,045
| -3% | -$247K | 0.47% | 64 |
|
|
2019
Q4 | $8.03M | Buy |
125,150
+29,573
| +31% | +$1.69M | 0.45% | 67 |
|
|
2019
Q3 | $4.85M | Sell |
95,577
-826
| -0.9% | -$38.8K | 0.29% | 89 |
|
|
2019
Q2 | $4.37M | Sell |
96,403
-1,953
| -2% | -$91K | 0.27% | 95 |
|
|
2019
Q1 | $4.69M | Sell |
98,356
-1,462
| -1% | -$72.8K | 0.3% | 89 |
|
|
2018
Q4 | $5.19M | Buy |
99,818
+404
| +0.4% | +$21.7K | 0.38% | 75 |
|
|
2018
Q3 | $6.17M | Buy |
99,414
+196
| +0.2% | +$11.6K | 0.39% | 80 |
|
|
2018
Q2 | $5.49M | Sell |
99,218
-2,326
| -2% | -$126K | 0.41% | 81 |
|
|
2018
Q1 | $6.42M | Sell |
101,544
-2,020
| -2% | -$130K | 0.44% | 72 |
|
|
2017
Q4 | $6.35M | Sell |
103,564
-240
| -0.2% | -$15K | 0.44% | 76 |
|
|
2017
Q3 | $6.62M | Sell |
103,804
-4,443
| -4% | -$259K | 0.48% | 73 |
|
|
2017
Q2 | $6.03M | Sell |
108,247
-400
| -0.4% | -$21.8K | 0.47% | 79 |
|
|
2017
Q1 | $5.91M | Sell |
108,647
-909
| -0.8% | -$49.9K | 0.47% | 78 |
|
|
2016
Q4 | $6.4M | Buy |
+109,556
| New | +$5.99M | 0.53% | 65 |
|
|
2015
Q4 | $6.41M | Buy |
+93,250
| New | +$6.16M | 0.67% | 50 |
|
|
2014
Q4 | $5.1M | Buy |
+86,371
| New | +$4.87M | 0.54% | 60 |
|
|
2013
Q4 | $5.22M | Buy |
+98,246
| New | +$5M | 0.6% | 51 |
|
Other funds holding BMY
VCM
VPM
Glenview Trust's BMY Position: Q1 2026 in Review
Glenview Trust increased its Bristol-Myers Squibb (BMY) stake by 0.33% in Q1 2026, buying an estimated $19.5K and bringing the position to 102,463 shares worth $6.21M. The position accounts for 0.1% of the portfolio, ranked #141.
Glenview Trust first reported a position in BMY in Q4 2013 and has held it in 41 quarters since. The position peaked at $8.23M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Glenview Trust held 102,463 shares of Bristol-Myers Squibb worth $6.21M as of Q1 2026.
- Glenview Trust bought 334 Bristol-Myers Squibb shares in Q1 2026, an estimated $19.5K.
- Bristol-Myers Squibb made up 0.1% of Glenview Trust's portfolio in Q1 2026, its #141 holding.
- Glenview Trust first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 41 quarters since.
- Glenview Trust's Bristol-Myers Squibb position peaked at $8.23M in Q2 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Glenview Trust's 13F filing for Q1 2026, filed 8 May 2026.